Last reviewed · How we verify

Severe growth hormone deficiency in adulthood — Treatment Landscape & Competitive Intelligence

Severe growth hormone deficiency in adulthood (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Severe growth hormone deficiency in adulthood, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Omnitrope Somatropin Serono Recombinant human growth hormone Dimeric GH receptors on cell membranes of target tissues 1976-01-01
Omnitrope Omnitrope Sandoz Growth hormone receptor
somatropine somatropine Sanofi Growth hormone receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Sandoz · 1 drug in Severe growth hormone deficiency in adulthood
  2. Sanofi · 1 drug in Severe growth hormone deficiency in adulthood
  3. Serono · 1 drug in Severe growth hormone deficiency in adulthood

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Severe growth hormone deficiency in adulthood:

Cite this brief

Drug Landscape (2026). Severe growth hormone deficiency in adulthood — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/severe-growth-hormone-deficiency-in-adulthood. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing